Immunicum AB (publ) today announced that the first patient has been enrolled in the Phase I ALISON clinical study evaluating DCP-001, the Company’s lead cancer relapse vaccine candidate, in High-Grade ...
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced the publication of updated clinical data from the ongoing ALISON ...
Immunicum AB (publ) today announced that the first patient has been enrolled in the Phase I ALISON clinical study evaluating DCP-001, the Company’s lead cancer relapse vaccine candidate, in High-Grade ...
ImmunicumAnnounces Enrollment of First Patient in Phase IALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer - First study evaluating cancer relapse vaccine candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback